Trial Profile
Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms HEROIC
- Sponsors Bayer
- 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2015 Planned End Date changed from 1 Jul 2015 to 1 May 2015, as reported by ClinicalTrials.gov.
- 11 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.